Analysts fell to the sidelines weighing in on Amgen (AMGN – Research Report) and Beam Therapeutics (BEAM – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Amgen (AMGN)
BMO Capital analyst Evan Seigerman maintained a Hold rating on Amgen today and set a price target of $260.00. The company’s shares closed last Monday at $283.80, close to its 52-week high of $296.67.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Amgen has an analyst consensus of Hold, with a price target consensus of $259.57, a -9.1% downside from current levels. In a report issued on December 1, Mizuho Securities also maintained a Hold rating on the stock with a $208.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Beam Therapeutics (BEAM)
In a report released today, Kostas Biliouris from BMO Capital maintained a Hold rating on Beam Therapeutics, with a price target of $61.00. The company’s shares closed last Monday at $44.50.
According to TipRanks.com, Biliouris is a 3-star analyst with an average return of
Currently, the analyst consensus on Beam Therapeutics is a Moderate Buy with an average price target of $73.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMGN:
- Amgen presents new Phase 1 AMG 133 data at WCIRDC 2022
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
- Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi
- Horizon Therapeutics confirms preliminary deal talks with Amgen, Janssen, Sanofi
